Navigation Links
CuraGen Announces Top-Line Phase II Results on Velafermin
Date:10/11/2007

- Conference call to be hosted today at 8:30 a.m. Eastern Time -

BRANFORD, Conn., Oct. 11 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Phase II dose-confirmatory clinical trial (CLN-12) evaluating a single dose of velafermin for the prevention of severe oral mucositis demonstrated that velafermin was safe and well-tolerated but did not meet its primary endpoint. Based on these results, the Company is discontinuing the development of velafermin, and will continue to focus its resources on belinostat, a Phase II histone deacetylase (HDAC) inhibitor for the treatment of solid tumors and hematologic malignancies, and CR011-vcMMAE, a Phase I/II antibody-drug conjugate for the treatment of metastatic melanoma.

"While we are disappointed that the primary endpoint was not met in this study, on behalf of everyone at CuraGen, I would like to thank all of the patients and investigators who took part in the velafermin development program," commented Timothy Shannon, President and Chief Executive Officer of CuraGen. "We continue to aggressively focus on our goal of advancing the belinostat and CR011-vcMMAE programs toward initiation of Phase III development in 2008, and we look forward to presenting updated clinical trial results on these programs in October at the AACR-NCI-EORTC conference, and in December at the ASH Annual Meeting."

CLN-12 was a randomized, double-blind, placebo-controlled study designed to assess a reduction in the incidence of severe Grade 3 or 4 oral mucositis in patients receiving high-dose chemotherapy followed by autologous bone marrow transplantation (BMT). The trial enrolled 390
'/>"/>

SOURCE CuraGen Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
3. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... the notice it received on May 21, 2015 from ... Company was below certain of the Exchange,s continued listing ... of the NYSE MKT Company Guide, due to the ...
(Date:7/30/2015)... COTTAGE, New York , July 30, 2015 /PRNewswire/ ... release of its latest report titled, "Continuous Glucose Monitoring ... - 2020". According to the report, the global continuous ... Mn in 2014 and is expected to reach US$ ... during the forecast period, 2015 to 2020. ...
(Date:7/30/2015)... MIAMI , July 30, 2015   ... latest update to UNI®, the world,s first operating ... simulators, is now available exclusively to Gaumard users. ... for recently launched Newborn Tory™ S2200, as well ... and monitoring of clinical measures such as EtCO ...
Breaking Medicine Technology:TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3
... N.J., Jan. 18, 2011 Fenwal, Inc. of Lake ... they have signed an agreement under which Fenwal will ... blood centers, plasma centers and hospitals in the United ... such as Genesis™ blood collection mixers and monitors, RapidSeal ...
... Inc. announced today that the U.S. Food & ... clearance to market the SImmetry™ Sacroiliac Joint Fusion ... intended for treating conditions including degenerative sacroiliitis and ... System consists of a range of threaded, cannulated ...
Cached Medicine Technology:Fenwal, GenesisBPS Enter Agreement for Blood-Specialty Products 2Zyga Technology, Inc. Receives FDA 510(K) Clearance for the SImmetry™ Sacroiliac Joint Fusion System 2
(Date:7/30/2015)... ... July 31, 2015 , ... Committed to helping the next generation succeed ... members to contribute to the College’s “My Brother’s Keeper Scholarship.” The President’s signature initiative ... on track. Providing the support they need to think more broadly about their future. ...
(Date:7/30/2015)... ... July 30, 2015 , ... As more hospitals across the ... recruiting patients becomes a serious challenge. Because of growing competition, it is more ... the local community. , The team at Wound Care Advantage has ...
(Date:7/30/2015)... ... 2015 , ... OSF Healthcare System has been recognized as one ... conducted by Hospitals & Health Networks. This marks the fourth consecutive year for this ... Sisters of the Third Order of St. Francis . , Health data security and ...
(Date:7/30/2015)... ... ... The connection between a healthy head of hair and a feeling of confidence is a ... hair can have a devastating impact on the daily life of a person. From ... consequences of hair loss are not to be taken lightly. , The skilled staff at ...
(Date:7/30/2015)... York, NY (PRWEB) , ... July 30, 2015 ... ... Setria®Glutathione and Sustamine® L-Alanyl-L-Glutamine for people on the go. With no water needed, ... Recovery Chewable as a simple way to get the natural ingredients that may ...
Breaking Medicine News(10 mins):Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4
... with cancer, the side effects of chemotherapy and ... drug-delivery research based on nano- and microtechnology from ... well as more effective cancer treatment. , New ... of Tel Aviv University,s Department of Biochemistry allows ...
... Perot Systems receives top ranking in Revenue Cycle Management ... -- For the second consecutive year, Perot Systems ... has received the #1 ranking in several categories of ... to the 2008 survey results, Perot Systems, Revenue ...
... A new analysis from the JUPITER study presented today ... California describes details of the stroke data according to ... adds to the primary analysis of the JUPITER study ... the risk of stroke by nearly half (48%; p=0.002), ...
... Create National Patient Registry, Increase Public Awareness of ... for Pulmonary Fibrosis (CPF) is excited to announce ... (PF) advocacy program -- the introduction of the ... in the 111th Congress. The PFREA, H.R. 1079, ...
... DALLAS, Feb. 19 Cholesterol-lowering statins, used by ... may falsely indicate thyroid problems, according to researchers ... studies, low serum TSH, and the influence of ... ."These findings could help physicians make quicker, more ...
... of Illinois reveals how a cellular protein recognizes an invading ... The research, described this week in the journal Science ... Medical Institute investigator Taekjip Ha, settles a debate over how ... viral RNA and self (or cellular) RNA. , "RIG-I ...
Cached Medicine News:Health News:New 'bubble' targets only cancer cells 2Health News:Perot Systems Ranked #1 Revenue Cycle Manager by Healthcare Providers 2Health News:Perot Systems Ranked #1 Revenue Cycle Manager by Healthcare Providers 3Health News:CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study 2Health News:CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study 3Health News:CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study 4Health News:Pulmonary Fibrosis Research Enhancement Act of 2009 Introduced in 111th U.S. Congress 2Health News:Pulmonary Fibrosis Research Enhancement Act of 2009 Introduced in 111th U.S. Congress 3Health News:Pulmonary Fibrosis Research Enhancement Act of 2009 Introduced in 111th U.S. Congress 4Health News:Dallas Scientists Discover Statins May Falsely Indicate Thyroid Problems 2Health News:Team learns how cellular protein detects viruses and sparks immune response 2
... pacing wire design offers reliable ... in the atrium and ventricle ... in one lead design. The ... ventricle are color-coded for easy ...
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: